ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 8, 2013, Pages 4679-4683

  Ozdemir, Ozer ^a   Ozdemir, Pelin ^a   Veral, Ali ^a   Uluer, Hatice ^a   Ozhan, Mustafa Hikmet ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

ERCC1; Lung cancer chemotherapy; Molecular markers; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DNA BINDING PROTEIN; DOCETAXEL; DRUG DERIVATIVE; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; GLUTAMIC ACID DERIVATIVE; GUANINE; IFOSFAMIDE; MITOMYCIN; PACLITAXEL; PEMETREXED; TAXOID; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FOLLOW-UP STUDIES; GLUTAMATES; GUANINE; HUMANS; IFOSFAMIDE; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885748989     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.8.4679     Document Type: Article

References (26)

1. Bepler G, Gautam A, McIntyre LM, et al (2002). Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol, 20, 1353-60.
2. Bepler G, Begum M, Simon GR (2008). Molecular analysis-based treatment strategies for non-small cell lung cancer. Cancer Control, 15, 130-9.
3. Bepler G, Williams C, Schell MJ, et al (2013). Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol, 31, 2404-12.
4. Breen D, Barlési F (2008). The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer. Eur J Cardiothorac Surg, 33, 805-11.
5. Ceppi P, Volante M, Novello S, et al (2006). ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol, 17, 1818-25.
6. Chen S, Zhang J, Wang R, Luo X, Chen H (2010). The platinum based treatments for advanced nonsmall cell lung cancer, is low/negative ERCC1 expression beter than high/positive ERCC1 expression? A metaanalysis. Lung Cancer, 70, 63-70.
7. Fink D, Zheng H, Nebel S (1997). In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res, 57, 1841-5.
8. Friboulet L, Olaussen KA, Pignon JP, et al (2013). ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med, 368, 1101-10.
9. Gao Z, Han B, Shen J, et al (2011). ERCC1 protein as a guide for individualized chemotherapy of late stage advanced non small cell lung cancer. Exp Ther Med, 2, 811-15.
10. Gomez-Roca C, Raynaud CM, Penault-Llorca F, et al (2009). Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol, 4, 1212-20.
11. th ed. Springer: New York.
12. th) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2, 694-705.
13. Italiano A, Burel-Vandenbos F, Otto J (2006). Comparison of the epidermal growth factor receptor gene and protein in primary nonsmall-cell lung cancer and metastatic sites: implications for treatment with EGFR inhibitors. Ann Oncol, 17, 981-5.
14. Lee HW, Choi YW, Han JH, et al (2009). Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum based doublet chemotherapy. Lung Cancer, 65, 377-82.
15. Lord RV, Brabender J, Gandara D, et al (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 8, 2286-91.
16. Ludovic C, Gillet J, Scharer OD (2006). Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev, 106, 253-76.
17. Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: The role of DNA repair pathways. Clin Cancer Res, 14, 1291-5.
18. Olaussen KA, Dunant A, Fouret P, et al (2006). DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355, 983-91.
19. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
20. Rosell R, Taron M, Barnadas A, et al (2003). Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer. Cancer Control, 10, 297-305.
21. Roth JA, Carlson JJ (2011). The prognostic role of ERCC1 in advanced non-small cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer, 12, 393-401.
22. Sekine I, Minna JD, Nishio K, Tamura T, Saijo N (2006). A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer. J Thorac Oncol, 1, 31-7.
23. Simon GR, Ismail-Khan R, Bepler G (2007). Nuclear excision repair-based personalized therapy for non-small cell lung cancer: From hypothesis to reality. Int J Biochem & Cell Biology, 39, 1318-28.
24. Taillade L, Penault-Llorca F, Boulet T, et al (2007). Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol, 18, 1043-50.
25. van Zandwijk N (2001). Neoadjuvant strategies for non-small cell lung cancer. Lung Cancer, 34, 145-50.
26. Zheng Z, Chen T, Li X, et al (2007). DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med, 356, 800-8.